Objective: A new autosomal dominant disorder due to mutation of THRA, which encodes thyroid hormone receptor a, is characterised by severely delayed skeletal development but only slightly abnormal thyroid status. Adult mice with disrupted thyroid hormone action in bone due to a mutation of Thra or deletion of Dio2, encoding the type 2 deiodinase, have high bone mass and mineralisation despite essentially euthyroid status. No individuals with DIO2 mutations have been described and the adult phenotype of patients with THRA mutations is largely unknown. We hypothesised that screening euthyroid adults with high bone mineral density (BMD) could be used to identify individuals with mutations of THRA or DIO2. Design: The Osteoporosis and Ultrasound Study (OPUS) is a 6-year prospective study of fracture-related factors from five European centres. Methods: A cohort of 100 healthy euthyroid post-menopausal women with the highest BMD was selected from the OPUS population. We sequenced the intron-exon boundaries and critical exons of THRA and DIO2 in these subjects. TSH, free 3,5,3 0 -L-triiodothyronine, free thyroxine, vitamin D, parathyroid hormone and bone turnover marker concentrations, and BMD measurements were available in all OPUS participants. Results: No coding sequence or splice site mutations affecting THRA or DIO2 were identified. Conclusions: Mutations affecting THRA or DIO2 are not a common cause of high BMD in healthy euthyroid post-menopausal women.
Introduction
Thyroid hormones (thyroxine (T 4 ) and 3, 5, 3 0 -L-triiodothyronine (T 3 )) are essential for skeletal development, post-natal growth, and bone maturation. In adults, thyroid hormones regulate bone turnover, and normal euthyroid status is required to maintain optimal bone mass and mineralisation (1) . Accordingly, thyrotoxicosis is a well-established cause of osteoporosis, and hypothyroidism is associated with an increased risk of fracture (2) .
The thyroid gland secretes T 4 and T 3 in a ratio of about 15:1, but T 4 is a pro-hormone and must be converted to T 3 in the peripheral tissues (3) . Conversion of T 4 to T 3 in target cells is catalysed by type 2 iodothyronine deiodinase (DIO2), and the activity of this enzyme regulates intracellular availability of T 3 . Two nuclear receptors, TRa and TRb, mediate T 3 action in the target cells, and their relative levels of expression vary between tissues.
For example, TRa is expressed at high levels in bone and cartilage, whereas TRb predominates in the hypothalamus and pituitary, where it mediates feedback control of the hypothalamic-pituitary-thyroid (HPT) axis (4) .
The syndrome of resistance to thyroid hormone (RTH) was described in 1967 (5) and the first THRB mutations affecting TRb were identified in 1989 (6) . Heterozygous mutations of THRA were finally reported in three families in 2012 and 2013 (7, 8, 9, 10) . Affected individuals all had grossly delayed skeletal development and constipation but variable motor and cognitive abnormalities. All had normal serum TSH with low/normal T 4 and high/normal T 3 concentrations, and a characteristically reduced free T 4 (fT 4 ):free T 3 (fT 3 ) ratio. A 6-year-old girl had skeletal dysplasia, growth retardation with delayed bone age and tooth eruption, patent skull sutures, macrocephaly, disproportionate short stature, epiphyseal dysgenesis and defective bone mineralisation (7) . A 3-year-old girl displayed a similar phenotype and also had congenital hip dislocation. Her 47-year-old father was short with height 3.77 S.D. below normal, and he had acquired hearing loss due to otosclerosis (9, 10). A 45-year-old female was described more recently with disproportionate short stature and macrocephaly, together with skull vault and long-bone cortical thickening (8) . These reports define a new genetic disorder characterised by profound developmental abnormalities of the skeleton due to mutations of THRA, although limited information is available regarding the phenotypic consequences in adults.
In patients with RTH, a spectrum of dominantnegative THRB mutations of varying severity have been defined, and they result in heterogeneous phenotypes. Nevertheless, because TRb is expressed in the hypothalamus and pituitary, even the least severe THRB mutations result in characteristic disruption of the HPT axis such that over 3000 affected individuals have been reported and many more have been recognised (11) . By analogy, it is likely that individuals with a spectrum of THRA mutations will be identified in the future. Significantly, the THRA mutations described so far result in a severe phenotype due to the expression of truncated TRa proteins with no T 3 -binding capability but potent dominant-negative activity (7, 8, 9, 10) . Recognition of individuals with milder mutations and phenotypes will be much more difficult because disruption of THRA does not affect the HPT axis significantly and alteration of circulating thyroid status is likely to be subtle.
Importantly, the phenotypes of individuals with THRA mutations recapitulate those reported in mice with dominant-negative mutations affecting Thra. Juvenile Thra1 PV/C mice have a reduced T 4 :T 3 ratio, delayed closure of the skull sutures with enlarged fontanelles, severe growth retardation and delayed bone age (12, 13) . Mice with a less severe Thra1 R384C mutation are euthyroid and have a much milder phenotype with only transiently delayed ossification and growth retardation, but they have reduced osteoclast numbers and display increased bone mass and cortical thickness in adults (14, 15) . Similarly, TRa 0/0 mice that lack TRa are euthyroid but have impaired osteoclastic bone resorption and high bone mass (16) , and D2KO mice that lack DIO2 have increased bone mineralisation and brittle bones but normal circulating T 3 (17) . Together with the phenotypes reported in individuals with THRA mutations, these data indicate that impaired T 3 action in the skeleton arising from defective TRa signalling or reduced T 3 availability results in high bone mass in adults without significant effect on systemic thyroid status. We hypothesised that adults with mutations affecting THRA or DIO2 would have increased bone mass and mineralisation but normal euthyroid status, and that such individuals might be identified by screening healthy euthyroid individuals with high bone mineral density (BMD). We tested this hypothesis by sequencing the THRA and DIO2 genes in 100 euthyroid subjects with high BMD from the Osteoporosis and Ultrasound Study (OPUS) (18) .
Subjects and methods

Osteoporosis and Ultrasound Study
OPUS is a prospective population-based study from five European centres and detailed information relating to the population demography and participant recruitment has been published previously (19) . The study was approved at each institution according to the Declaration of Helsinki and written consent was obtained from all participants. A total of 2374 post-menopausal women were recruited between April 1999 and April 2001.
Measurement of BMD
Dual-energy X-ray absorptiometry scans of the lumbar spine (L2-L4) and hip were performed on all participants in postero-anterior projection (Hologic QDR-4500, Hologic, Inc., Bedford, MA, USA) in Kiel, Paris and Sheffield, or in antero-posterior projection (Lunar Expert devices; GE Lunar Corp., Madison, WI, USA) in Aberdeen and Berlin. Results were corrected for longitudinal changes and for differences among centres, and were expressed as standardised BMD (sBMD) as described (18) .
Study cohort
The current study is a cohort study of healthy euthyroid post-menopausal women selected from the OPUS population. Thyroid status was determined in all individuals and reference intervals for fT 3 , fT 4 and TSH calculated as described (18) . The following subjects were excluded initially in order to define a healthy euthyroid cohort: individuals with overt thyroid disease (TSH O10 mU/l and fT 4 !9 pmol/l; or TSH O10 mU/l and fT 3 !2.5 pmol/l; or TSH !0.1 mU/l and fT 3 O6 pmol/l), renal disease or cancer; and those with sick thyroid syndrome defined as subjects with an isolated fT 3 concentration !2.5 pmol/l associated with a malabsorption syndrome including coeliac or Crohn's disease, rheumatoid arthritis, bone disease other than osteoarthritis, psoriasis or asthma. Subjects taking T 4 , antiepileptics, glucocorticoids or other drugs affecting bone metabolism were also excluded, resulting in 1278 healthy euthyroid post-menopausal women not receiving drugs affecting bone metabolism (18) .
The sBMD values of all 1278 individuals were ranked, and the 100 subjects with the highest sBMD from whom stored DNA samples were available were selected (Fig. 1) . Sequencing of THRA was performed in all 100 subjects (200 alleles), and sufficient DNA was available for further sequencing of DIO2 in only 48 of these 100 subjects (96 alleles).
DNA samples
Genomic DNA was extracted from stored blood samples in Sheffield and stored in 50 ml aliquots at K80 8C before shipment and analysis at Imperial College. The DNA concentration in each sample was determined using a Picogreen DNA quantitation kit (Cambridge Biosciences, Cambridge, UK), according to the manufacturer's instructions. Fluorescence Figure 1 Exclusion criteria to define the study cohort of 1278 healthy euthyroid post-menopausal women not receiving drugs affecting bone metabolism, and the 100 subjects with the highest standardised bone mineral density from whom stored DNA samples were available.
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and incubation at 72 8C for 2 min. PCR products were purified using ExoSAP, with 20 U/ml exonuclease I (New England Biolabs, Hitchin, UK) and 1 U/ml shrimp alkaline phosphatase (Promega UK) in preparation for direct sequencing. Mixtures containing 10 ng/100 bp of purified PCR product and 3.2 pmol of primer were prepared in 10 ml reaction volumes for cycle sequencing with BigDye v3.1 (Applied Biosystems, Life Technologies Ltd) in the Genomics Core Laboratory at Hammersmith Campus, Imperial College. The samples were denatured at 94 8C for 1 min followed by 30 cycles of 94 8C for 10 s, 55 8C for 15 s and 60 8C for 4 min. The products were precipitated in EDTA-ethanol, suspended in Hi-Di formamide (Applied Biosystems) and sequenced using a 3730xl DNA Analyzer (Applied Biosystems). Sequences analysis was performed using Sequencher v4.7 software (Gene Codes Corporation, Ann Arbor, MI, USA).
Statistical analysis
Analyses were performed using SPSS v.21 (SPSS, Inc.) or GraphPad Prism v5 (GraphPad Software, Inc., San Diego, CA, USA). The Kolmogorov-Smirnov test was used to test data for normal distribution. All normally distributed data were presented as meanGS.D., whereas non-parametric data (logarithmically transformed TSH values) were presented as median and range. Comparisons between groups were performed using Student's t-test or MannWhitney U test. Stepwise regression analysis was performed to investigate the associations between fT 4 :fT 3 ratio and BMD or bone turnover markers.
Results
Study cohort and high BMD groups
Compared with the total cohort of 1278 healthy euthyroid post-menopausal women, the group of 100 subjects with increased hip and lumbar spine BMD, in which the THRA (nZ100) or DIO2 (nZ48 of these 100 subjects) genes were sequenced, had reduced concentrations of bone resorption (serum C-terminal telopeptide (sbCTX), urinary N-terminal telopeptide of type I collagen (uNTX)) and formation (osteocalcin (OC), procollagen type I N-terminal propeptide (PINP)) markers. By contrast, the fT 4 :fT 3 ratio and TSH, fT 3 , fT 4 , vitamin D and parathyroid hormone (PTH) concentrations did not differ between groups ( Table 2 ). The fT 4 :fT 3 ratio was not associated with changes in hip and lumbar spine BMD or bone turnover markers (Table 3) .
Analysis of THRA
Sequencing of intron-exon boundaries and coding exons of THRA in 100 subjects with high BMD revealed no coding sequence or splice site mutations in THRA (NCBI mRNA reference sequences: NM_199334.3 and NM_003250.5). The rs2230701 single nucleotide polymorphism in exon 5 (GCC/GCT; Ala/Ala) was identified at allele and genotype frequencies ( compared with subjects homozygous for the major allele (GCC); however, there were no differences in PINP and uNTX/Cr levels and hip or lumbar spine BMD among subjects of differing rs2230701 genotype (Table 4) .
Analysis of DIO2
Sequencing of DIO2 in 48 of the 100 subjects with high BMD also revealed no coding sequence or splice site mutations in DIO2 (NCBI mRNA reference sequences: NM_013989.4; NM_000793.5; NM_001007023.3; NM_001242502.1 and NM_001242503.1). The rs225014 polymorphism in exon 2 (ACA/GCA; Thr92Ala) was identified at allele and genotype frequencies (Table 4) consistent with previous reports (22, 23, 24) and established databases. Bone turnover marker concentrations and hip or lumbar spine BMD was not different among subjects of differing rs225014 genotype (Table 4) .
Discussion
The recent identification of severely delayed skeletal development in patients with potent dominant-negative mutations of THRA (7, 8, 9, 10) recapitulated the findings in juvenile mice with Thra mutations (12, 13, 14, 16) . Studies in mice with deletion or mutation of Thra or Dio2 demonstrated further that impaired T 3 action in bone results in high BMD in adults despite normal circulating thyroid status (14, 16, 17) . Despite this, little information is available regarding the adult skeletal consequences of severe THRA mutations, whilst no individuals with less deleterious THRA mutations or patients with DIO2 mutations have been described. A candidate gene association study of 862 men over 65 years of age investigated the relationships between genetic variation in THRA and BMD at the femoral neck and lumbar spine (25, 26) , whilst a much larger study investigated the THRA locus in relation to BMD, fracture risk and bone geometry in 27 326 individuals from the Genetic Factors for Osteoporosis (GEFOS) consortium and the Rotterdam Study 1 and 2 populations (21). These studies did not identify any relationships between variation in bone parameters and genetic variation across the THRA locus. Furthermore, osteoporosis genome-wide association (GWA) studies have not identified associations between THRA or DIO2 and BMD or fracture (27, 28, 29, 30) . This is not surprising because GWA studies investigate common variation among very large numbers of SNPs across the entire genome to identify genetic associations with quantitative traits (31), and they are not designed to detect rare sequence variants or causative mutations for single gene disorders (32) . By contrast, studies of phenotype extremes in humans have been instrumental in identifying molecular mechanisms underlying rare single gene disorders as well as common diseases, including diabetes and obesity.
Such studies have resulted in novel treatments that revolutionise the lives of affected individuals (33, 34, 35) .
We adopted such a strategy by investigating whether screening of euthyroid adults with high BMD could be a novel and practical approach to identify patients with DIO2 mutations or individuals with mild mutations affecting THRA. These studies did not identify coding sequence or splice site mutations affecting THRA or DIO2 in 100 individuals with high BMD from the cohort of healthy euthyroid post-menopausal women, indicating that such mutations are unlikely to be a common cause of increased BMD in healthy euthyroid post-menopausal women.
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